Market Overview

Acorda Therapeutics Shares Down 21.3% After Earlier Report It Has Lost An Patent Court Appeal Ruling Regarding The Drug Ampyra, Affirming A Trial Ruling In Favor Of Teva and Mylan

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News FDA Movers Trading Ideas General

 

Related Articles (ACOR + MYL)

Industrial Hemp Looks Secure In Farm Bill Despite Looming Delay

This Day In Market History: The South Sea Co. Charters